| NCT ID | NCT07309718 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | ICAS - Intracranial Atherosclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-12-01 with a primary completion date of 2027-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 to 80 years. 2. Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation. 3. Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA. 4. Written informed consent obtained from the participant or a legal representative. Exclusion Criteria: 1. Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital/genetic abnormalities. 2. More than 50% stenosis of the extracranial carotid artery on the ipsilateral side. 3. Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3. 4. Contraindications to antiplatelet therapy or statins. 5. Inability to undergo MRI due to metal implants or claustrophobia.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07309718 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying ICAS - Intracranial Atherosclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07309718 currently recruiting?
Yes, NCT07309718 is actively recruiting participants. Contact the research team at luojichang_dr@sina.com for enrollment information.
Where is the NCT07309718 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07309718 clinical trial?
NCT07309718 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 400 participants.